+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Non-alcoholic Steatohepatitis Biomarkers Market Size, Share & Trends Analysis Report by Type (Serum, Hepatic Fibrosis, Apoptosis, Oxidative Stress), by End-use (Pharma & CRO Industry, Hospitals), by Region, and Segment Forecasts, 2022-2030

  • PDF Icon

    Report

  • 120 Pages
  • October 2022
  • Region: Global
  • Grand View Research
  • ID: 4375434
The global non-alcoholic steatohepatitis biomarkers market size is expected to reach USD 5.4 billion by 2030, registering a CAGR of 23.6% during the forecast period. The growth of the Non-alcoholic Steatohepatitis (NASH) biomarkers market is attributed to rising prevalence of chronic diseases and rising demand for providing novel diagnostic tools. Nonalcoholic Fatty Liver Disease (NAFLD) is more prevalent in people with specific diseases, such as obesity, and diseases that may be linked to obesity, including type 2 diabetes. One-third to two-thirds of people with type 2 diabetes are projected to have NAFLD.

According to April 2021 study by NIH, up to 75% of overweight individuals and more than 90% of individuals with extreme obesity have NAFLD. An increasing obese population and unhealthy food habits are creating a favorable environment for the development of liver disease. Therefore, the rising prevalence of chronic liver disease is expected to fuel the demand for NASH biomarkers. The ongoing research activities in this sector are likely to sustain the market growth.

The primary factor pertaining to growth is the increasing incidence of chronic liver illnesses like nonalcoholic steatohepatitis and the need to develop ways for their early detection and diagnosis. The market for non-alcoholic steatohepatitis biomarkers has enormous growth potential despite the lack of a single reliable non-invasive procedure to diagnose NAFLD. Another growth factor is the increasing demand for non-invasive diagnosis methods as other diagnostic procedures available are intrusive and expensive, thus they are not suitable for patients.

Moreover, major key players operating in the market are focusing on collaborations aiming toward expanding awareness among the population is further propelling the growth of market. For instance, in June 2022, Echosens and Novo Nordisk announced a partnership to increase awareness about NASH and accelerate the adoption rate of noninvasive screening methods such as Echosens’ FibroScan system. The partnership strives to double the diagnosis rate of severe and advanced NASH by 2025.

The high cost of diagnosing NASH is a significant factor hindering the growth of the market. For instance, liver biopsy for NASH for monitoring and diagnosis of the disease can cost up to USD 3500 making it an invasive and expensive procedure. Furthermore, regulatory authorities such as the FDA have strict rules for biomarker approval, which is slowing industry expansion.

Non-alcoholic Steatohepatitis Biomarkers Market Report Highlights

  • By type, the serum biomarkers segment held a larger share of the NASH biomarkers market since serum biomarkers are most effective and most widely used diagnosis tool
  • By end-use, the pharma & CRO industry segment is expected to show the fastest growth over the forecast period due to the high demand for non-invasive tools for the diagnosis of liver diseases
  • North America dominated the global market in 2021, owing to the rising prevalence of infectious diseases, cardiovascular diseases, and cancer
  • Key players operating in the market are focusing on collaborations and partnerships focusing on expanding the awareness about early diagnosis and presence of diagnostic tools for determining NAFLD and NASH


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Non-alcoholic Steatohepatitis Biomarkers Market

What is the estimated value of the Global Non-alcoholic Steatohepatitis Biomarkers Market?

The Global Non-alcoholic Steatohepatitis Biomarkers Market was estimated to be valued at $982.1 Million in 2022.

What is the growth rate of the Global Non-alcoholic Steatohepatitis Biomarkers Market?

The growth rate of the Global Non-alcoholic Steatohepatitis Biomarkers Market is 23.6%, with an estimated value of $5400 Million by 2030.

What is the forecasted size of the Global Non-alcoholic Steatohepatitis Biomarkers Market?

The Global Non-alcoholic Steatohepatitis Biomarkers Market is estimated to be worth $5400 Million by 2030.

Who are the key companies in the Global Non-alcoholic Steatohepatitis Biomarkers Market?

Key companies in the Global Non-alcoholic Steatohepatitis Biomarkers Market include Genfit, Prometheus Laboratories, Astrazeneca, Siemens Medical Solutions Usa, Inc., Bristol, Myers Squibb Company, Biopredictive, Quest Diagnostics, Exalenz Bioscience Ltd and Pfizer, Inc..

Table of Contents

Chapter 1 NASH Biomarkers Market: Methodology and Scope
1.1 Research Methodology
1.2 Research Assumptions
1.2.1 Estimates and forecast timeline
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity flow analysis
1.6.1.1 Approach 1: Commodity flow approach
1.6.2 Volume price analysis (model 2)
1.6.2.1 Approach 2: Volume price analysis
1.6.2.2 Revenue modeling
1.7 List of Secondary Sources
1.8 List of Primary Sources
Chapter 2 NASH Biomarkers Market: Executive Summary
2.1 Market Summary
Chapter 3 NASH Biomarkers Market: Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Rising prevalence of chronic liver diseases
3.3.1.2 Increasing demand for non-invasive diagnostics for NASH biomarkers
3.3.1.3 Rising investment by government and private organizations in R&D for NASH biomarkers therapeutics
3.3.2 Market Restraint Analysis
3.3.2.1 Side-effects and risks associated with NASH therapeutics
3.4 Porter’s Five Forces Analysis
3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.6 Regulatory Framework
3.7 Pipeline Analysis
Chapter 4 NASH Biomarkers Market: Competitive Landscape
4.1 Recent developments & impact analysis, by key market participants
4.1.1 Ansoff Matrix
4.2 Major deals & strategic alliances analysis
4.2.1 Joint Ventures
4.2.2 Licensing and Partnerships
4.2.3 Technological Collaborations
4.3 Company/Competition Categorization
4.4 Vendor Landscape
4.4.1 List Of Key Distributors and Channel Partners
4.4.2 Key Customers
4.5 Public Companies
4.5.1 Company Market Position Analysis
4.6 Private Companies
4.6.1 List Of Key Emerging Companies
4.6.2 Regional Network Map
Chapter 5 NASH Biomarkers Market: Type Business Analysis
5.1 Definition and Scope
5.2 Type Market Share Analysis, 2021 & 2030
5.3 Global NASH Biomarkers Market, By Type, 2018 To 2030
5.4 Market Size & Forecasts and Trend Analyses, 2018 to 2030
5.4.1 Serum Biomarkers
5.4.1.1 Serum Biomarkers Market 2018 - 2030 (USD Million)
5.4.2 Hepatic Fibrosis Biomarkers
5.4.2.1 Hepatic Fibrosis Biomarkers Market, 2018 - 2030 (USD Million)
5.4.3 Apoptosis Biomarkers
5.4.3.1 Apoptosis Biomarkers Market, 2018 - 2030 (USD Million)
5.4.4 Oxidative Stress Biomarkers
5.4.4.1 Oxidative Stress Biomarkers Market, 2018 - 2030 (USD Million)
5.4.5 Others
5.4.5.1 Others Market, 2018 - 2030 (USD Million)
Chapter 6 NASH Biomarkers Market: End-Use Business Analysis
6.1 Definition and Scope
6.2 End-Use Market Share Analysis, 2021 & 2030
6.3 Global NASH Biomarkers Market, By End-Use, 2018 To 2030
6.4 Market Size & Forecasts and Trend Analyses, 2018 to 2030
6.4.1 Pharma & CRO Industry
6.4.1.1 Pharma & CRO Industry Market 2018 - 2030 (USD Million)
6.4.2 Hospitals
6.4.2.1 Hospitals Market, 2018 - 2030 (USD Million)
6.4.3 Diagnostic Labs
6.4.3.1 Diagnostic Labs Market, 2018 - 2030 (USD Million)
6.4.4 Academic Research Institutes
6.4.4.1 Academic Research Institutes Market, 2018 - 2030 (USD Million)
Chapter 7 NASH Biomarkers Market: Regional Business Analysis
7.1 Definition & Scope
7.2 Regional Market Share Analysis, 2021 & 2030
7.3 Regional Market Dashboard
7.4 Regional Market Snapshot
7.5 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
7.5.1 North America
7.5.2 Europe
7.5.3 Asia Pacific
7.5.4 Latin America
7.5.5 MEA
7.6 Market Size, & Forecasts, Trend Analysis, 2021 to 2030
7.7 North America
7.7.1 North America NASH Biomarkers Market, 2018 - 2030 (USD Million)
7.7.2 U.S.
7.7.2.1 U.S. NASH Biomarkers Market, 2018 - 2030 (USD Million)
7.7.3 Canada
7.7.3.1 Canada NASH Biomarkers Market, 2018 - 2030 (USD Million)
7.8 Europe
7.8.1 Europe NASH Biomarkers Market, 2018 - 2030 (USD Million)
7.8.2 U.K.
7.8.2.1 U.K. NASH Biomarkers Market, 2018 - 2030 (USD Million)
7.8.3 Germany
7.8.3.1 Germany NASH Biomarkers Market, 2018 - 2030 (USD Million)
7.8.4 France
7.8.4.1 France NASH Biomarkers Market, 2018 - 2030 (USD Million)
7.8.5 Italy
7.8.5.1 Italy NASH Biomarkers Market, 2018 - 2030 (USD Million)
7.8.6 Spain
7.8.6.1 Spain NASH Biomarkers Market, 2018 - 2030 (USD Million)
7.9 Asia Pacific
7.9.1 Asia Pacific NASH Biomarkers Market, 2018 - 2030 (USD Million)
7.9.2 Japan
7.9.2.1 Japan NASH Biomarkers Market, 2018 - 2030 (USD Million)
7.9.3 China
7.9.3.1 China NASH Biomarkers Market, 2018 - 2030 (USD Million)
7.9.4 India
7.9.4.1 India NASH Biomarkers Market, 2018 - 2030 (USD Million)
7.9.5 Australia
7.9.5.1 Australia NASH Biomarkers Market, 2018 - 2030 (USD Million)
7.9.6 South Korea
7.9.6.1 South Korea NASH Biomarkers Market, 2018 - 2030 (USD Million)
7.10 Latin America
7.10.1 Latin America NASH Biomarkers Market, 2018 - 2030 (USD Million)
7.10.2 Brazil
7.10.2.1 Brazil NASH Biomarkers Market, 2018 - 2030 (USD Million)
7.10.3 Mexico
7.10.3.1 Mexico NASH Biomarkers Market, 2018 - 2030 (USD Million)
7.10.4 Argentina
7.10.4.1 Argentina NASH Biomarkers Market, 2018 - 2030 (USD Million)
7.11 MEA
7.11.1 MEA NASH Biomarkers Market, 2018 - 2030 (USD Million)
7.11.2 South Africa
7.11.2.1 South Africa NASH Biomarkers Market, 2018 - 2030 (USD Million)
7.11.3 Saudi Arabia
7.11.3.1 Saudi Arabia NASH Biomarkers Market, 2018 - 2030 (USD Million)
7.11.4 UAE
7.11.4.1 UAE NASH Biomarkers Market, 2018 - 2030 (USD Million)
Chapter 8 NASH Biomarkers Market: Company Profiling
8.1 Company Profiles
8.1.1. GENFIT
8.1.1.1 Company overview
8.1.1.2 Financial performance
8.1.1.3 Product benchmarking
8.1.1.4 Strategic initiatives
8.1.2. Prometheus Laboratories
8.1.2.1 Company overview
8.1.2.2 Financial performance
8.1.2.3 Product benchmarking
8.1.2.4 Strategic initiatives
8.1.3. AstraZeneca
8.1.3.1 Company overview
8.1.3.2 Financial performance
8.1.3.3 Product benchmarking
8.1.3.4 Strategic initiatives
8.1.4. Siemens Medical Solutions USA, Inc.
8.1.4.1 Company overview
8.1.4.2 Financial performance
8.1.4.3 Product benchmarking
8.1.4.4 Strategic initiatives
8.1.5. Bristol-Myers Squibb Company
8.1.5.1 Company overview
8.1.5.2 Financial performance
8.1.5.3 Product benchmarking
8.1.5.4 Strategic initiatives
8.1.6. BioPredictive
8.1.6.1 Company overview
8.1.6.2 Financial performance
8.1.6.3 Product benchmarking
8.1.6.4 Strategic initiatives
8.1.7. Quest Diagnostics
8.1.7.1 Company overview
8.1.7.2 Financial performance
8.1.7.3 Product benchmarking
8.1.7.4 Strategic initiatives
8.1.8 Exalenz Bioscience Ltd
8.1.8.1 Company overview
8.1.8.2 Financial performance
8.1.8.3 Product benchmarking
8.1.8.4 Strategic initiatives
8.1.9 Pfizer, Inc.
8.1.9.1 Company overview
8.1.9.2 Financial performance
8.1.9.3 Product benchmarking
8.1.9.4 Strategic initiatives
8.1.10 Laboratory Corporation of America Holdings
8.1.10.1 Company overview
8.1.10.2 Financial performance
8.1.10.3 Product benchmarking
8.1.10.4 Strategic initiatives
List of Tables
Table 1 List of Secondary Sources
TABLE 2 List of Abbreviations
TABLE 3 Regulatory Framework
TABLE 4 Global NASH Biomarkers Market, By Region, 2018-2030 (USD Million)
TABLE 5 Global NASH Biomarkers Market, By Type, 2018-2030 (USD Million)
TABLE 6 Global NASH Biomarkers Market, By End-use, 2018-2030 (USD Million)
TABLE 7 North America NASH Biomarkers Market, By Country, 2018-2030 (USD Million)
TABLE 8 North America NASH Biomarkers Market, By Type, 2018-2030 (USD Million)
TABLE 9 North America NASH Biomarkers Market, By End-use, 2018-2030 (USD Million)
TABLE 10 U.S. NASH Biomarkers Market, By Type, 2018-2030 (USD Million)
TABLE 11 U.S. NASH Biomarkers Market, By End-use, 2018-2030 (USD Million)
TABLE 12 Canada NASH Biomarkers Market, By Type, 2018-2030 (USD Million)
TABLE 13 Canada NASH Biomarkers Market, By End-use, 2018-2030 (USD Million)
TABLE 14 Europe NASH Biomarkers Market, By Country, 2018-2030 (USD Million)
TABLE 15 Europe NASH Biomarkers Market, By Type, 2018-2030 (USD Million)
TABLE 16 Europe NASH Biomarkers Market, By End-Use, 2018-2030 (USD Million)
TABLE 17 U.K. NASH Biomarkers Market, By Type, 2018-2030 (USD Million)
TABLE 18 U.K. NASH Biomarkers Market, By End-Use, 2018-2030 (USD Million)
TABLE 19 Germany NASH Biomarkers Market, By Type, 2018-2030 (USD Million)
TABLE 20 Germany NASH Biomarkers Market, By End-Use, 2018-2030 (USD Million)
TABLE 21 France NASH Biomarkers Market, By Type, 2018-2030 (USD Million)
TABLE 22 France NASH Biomarkers Market, By End-Use, 2018-2030 (USD Million)
TABLE 23 Spain NASH Biomarkers Market, By Type, 2018-2030 (USD Million)
TABLE 24 Spain NASH Biomarkers Market, By End-Use, 2018-2030 (USD Million)
TABLE 25 Italy NASH Biomarkers Market, By Type, 2018-2030 (USD Million)
TABLE 26 Italy NASH Biomarkers Market, By End-Use, 2018-2030 (USD Million)
TABLE 27 Asia Pacific NASH Biomarkers Market, By Country, 2018-2030 (USD Million)
TABLE 28 Asia Pacific NASH Biomarkers Market, By Type, 2018-2030 (USD Million)
TABLE 29 Asia Pacific NASH Biomarkers Market, By End-Use, 2018-2030 (USD Million)
TABLE 30 China NASH Biomarkers Market, By Type, 2018-2030 (USD Million)
TABLE 31 China NASH Biomarkers Market, By End-Use, 2018-2030 (USD Million)
TABLE 32 Japan NASH Biomarkers Market, By Type, 2018-2030 (USD Million)
TABLE 33 Japan NASH Biomarkers Market, By End-Use, 2018-2030 (USD Million)
TABLE 34 India NASH Biomarkers Market, By Type, 2018-2030 (USD Million)
TABLE 35 India NASH Biomarkers Market, By End-Use, 2018-2030 (USD Million)
TABLE 36 South Korea NASH Biomarkers Market, By Type, 2018-2030 (USD Million)
TABLE 37 South Korea NASH Biomarkers Market, By End-Use, 2018-2030 (USD Million)
TABLE 38 Australia NASH Biomarkers Market, By Type, 2018-2030 (USD Million)
TABLE 39 Australia NASH Biomarkers Market, By End-Use, 2018-2030 (USD Million)
TABLE 40 Latin America NASH Biomarkers Market, By Country, 2018-2030 (USD Million)
TABLE 41 Latin America NASH Biomarkers Market, By Type, 2018-2030 (USD Million)
TABLE 42 Latin America NASH Biomarkers Market, By End-Use, 2018-2030 (USD Million)
TABLE 43 Brazil NASH Biomarkers Market, By Type, 2018-2030 (USD Million)
TABLE 44 Brazil NASH Biomarkers Market, By End-Use, 2018-2030 (USD Million)
TABLE 45 Mexico NASH Biomarkers Market, By Type, 2018-2030 (USD Million)
TABLE 46 Mexico NASH Biomarkers Market, By End-Use, 2018-2030 (USD Million)
TABLE 47 Argentina NASH Biomarkers Market, By Type, 2018-2030 (USD Million)
TABLE 48 Argentina NASH Biomarkers Market, By End-Use, 2018-2030 (USD Million)
TABLE 49 MEA NASH Biomarkers Market, By Country, 2018-2030 (USD Million)
TABLE 50 MEA NASH Biomarkers Market, By Type, 2018-2030 (USD Million)
TABLE 51 MEA NASH Biomarkers Market, By End-Use, 2018-2030 (USD Million)
TABLE 52 South Africa NASH Biomarkers Market, By Type, 2018-2030 (USD Million)
TABLE 53 South Africa NASH Biomarkers Market, By End-Use, 2018-2030 (USD Million)
TABLE 54 Saudi Arabia NASH Biomarkers Market, By Type, 2018-2030 (USD Million)
TABLE 55 Saudi Arabia NASH Biomarkers Market, By End-Use, 2018-2030 (USD Million)
TABLE 56 UAE NASH Biomarkers Market, By Type, 2018-2030 (USD Million)
TABLE 57 UAE NASH Biomarkers Market, By End-Use, 2018-2030 (USD Million)
List of Figures
Fig. 1 Market Research Process
FIG. 2 Information Procurement
FIG. 3 Primary Research Pattern
FIG. 4 Market Research Approaches
FIG. 5 Value Chain-Based Sizing & Forecasting
FIG. 6 Market Formulation & Validation
FIG. 7 NASH Biomarkers Market Segmentation
FIG. 8 Market Driver Relevance Analysis (Current & Future Impact)
FIG. 9 Market Restraint Relevance Analysis (Current & Future Impact)
FIG. 10 Market Challenge Relevance Analysis (Current & Future Impact)
FIG. 11 Penetration & Growth Prospect Mapping
FIG. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
FIG. 13 Porter’s Five Forces Analysis
FIG. 14 Market Penetration & Growth Prospect Mapping
FIG. 15 NASH Biomarkers Market: Type Movement Analysis
FIG. 16 Serum biomarkers market, 2018-2030 (USD Million)
FIG. 17 Hepatic fibrosis biomarkers market, 2018-2030 (USD Million)
FIG. 18 Apoptosis biomarkers market, 2018-2030 (USD Million)
FIG. 19 Oxidative stress biomarkers market, 2018-2030 (USD Million)
FIG. 20 Others market, 2018-2030 (USD Million)
FIG. 21 NASH Biomarkers Market: End-use Movement Analysis
FIG. 22 Pharma & CRO Industry market, 2018-2030 (USD Million)
FIG. 23 Hospitals market, 2018-2030 (USD Million)
FIG. 24 Diagnostic Labs market, 2018-2030 (USD Million)
FIG. 25 Academic Research Institutes market, 2018-2030 (USD Million)
FIG. 26 Regional Marketplace: Key Takeaways
FIG. 27 Regional Outlook, 2018 & 2030
FIG. 28 Regional Market Dashboard
FIG. 29 Regional Market Place: Key Takeaways
FIG. 30 North America, SWOT Analysis
FIG. 31 Europe, SWOT Analysis
FIG. 32 Asia Pacific, SWOT Analysis
FIG. 33 Latin America, SWOT Analysis
FIG. 34 MEA, SWOT Analysis
FIG. 35 North America
FIG. 36 North America Market Estimates And Forecast, 2018-2030 (USD Million)
FIG. 37 U.S.
FIG. 38 U.S. Market Estimates And Forecast, 2018-2030 (USD Million)
FIG. 39 Canada
FIG. 40 Canada Market Estimates And Forecast, 2018-2030 (USD Million)
FIG. 41 Europe
FIG. 42 Europe Market Estimates And Forecast, 2018-2030 (USD Million)
FIG. 43 UK
FIG. 44 UK Market Estimates And Forecast, 2018-2030 (USD Million)
FIG. 45 Germany
FIG. 46 Germany Market Estimates And Forecast, 2018-2030 (USD Million)
FIG. 47 France
FIG. 48 France Market Estimates And Forecast, 2018-2030 (USD Million)
FIG. 49 Italy
FIG. 50 Italy Market Estimates And Forecast, 2018-2030 (USD Million)
FIG. 51 Spain
FIG. 52 Spain Market Estimates And Forecast, 2018-2030 (USD Million)
FIG. 53 Asia Pacific
FIG. 54 Asia-Pacific Market Estimates And Forecast, 2018-2030 (USD Million)
FIG. 55 Japan
FIG. 56 Japan Market Estimates And Forecast, 2018-2030 (USD Million)
FIG. 57 China
FIG. 58 China Market Estimates And Forecast, 2018-2030 (USD Million)
FIG. 59 India
FIG. 60 India Market Estimates And Forecast, 2018-2030 (USD Million)
FIG. 61 Australia
FIG. 62 Australia Market Estimates And Forecast, 2018-2030 (USD Million)
FIG. 63 South Korea
FIG. 64 South Korea Market Estimates And Forecast, 2018-2030 (USD Million)
FIG. 65 Latin America
FIG. 66 Latin America Market Estimates And Forecast, 2018-2030 (USD Million)
FIG. 67 Brazil
FIG. 68 Brazil Market Estimates And Forecast, 2018-2030 (USD Million)
FIG. 69 Mexico
FIG. 70 Mexico Market Estimates And Forecast, 2018-2030 (USD Million)
FIG. 71 Argentina
FIG. 72 Argentina Market Estimates And Forecast, 2018-2030 (USD Million)
FIG. 73 MEA
FIG. 74 MEA Market Estimates And Forecast, 2018-2030 (USD Million)
FIG. 75 South Africa
FIG. 76 South Africa Market Estimates And Forecast, 2018-2030 (USD Million)
FIG. 77 Saudi Arabia
FIG. 78 Saudi Arabia Market Estimates And Forecast, 2018-2030 (USD Million)
FIG. 79 UAE
FIG. 80 UAE Market Estimates And Forecast, 2018-2030 (USD Million)
FIG. 81 Strategy Mapping

Companies Mentioned

  • Genfit
  • Prometheus Laboratories
  • Astrazeneca
  • Siemens Medical Solutions Usa, Inc.
  • Bristol-Myers Squibb Company
  • Biopredictive
  • Quest Diagnostics
  • Exalenz Bioscience Ltd
  • Pfizer, Inc.
  • Laboratory Corporation of America Holdings

Methodology

Loading
LOADING...